Notice Regarding Reorganization of Subsidiary through Company Merger

OSAKA, Japan, 30, November, 2021 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "Shionogi") announced Shionogi has resolved at a meeting of the Board of Directors on November 29, 2021 to have Shionogi Pharma (Head Office: Osaka, Japan; President and CEO: Ryuichi Kume, Ph.D.; hereafter "Shionogi Pharma") , a wholly owned subsidiary of Shionogi, implement an absorption-type merger (hereafter “Merger”) with Nagase Medicals Co., Ltd. (Head Office: Itami, Hyogo, Japan; Representative Director and President: Mitsuru Akasaka; hereafter “Nagase Medicals”), a wholly owned subsidiary of Shionogi Pharm, aiming for completion of the Merger by April 1, 2022.

1. Purpose of Merger

Shionogi Pharma aims to become the “most trusted one-stop CDMO*", and is expanding its business of manufacturing, sale, analytical testing and pharmaceutical engineering of medicinal drugs and investigational drugs. Nagase Medicals, a wholly owned subsidiary of Shionogi Pharma from October 1, 2020, is involved in the contract manufacture of high value-added healthcare products, focusing on highly potent injectable pharmaceuticals.

The Merger of the two businesses aims to create a faster and higher quality full-range CDMO and solutions business to increase customer value and drive growth as a technological innovation-focused manufacturing company. Through establishing a new business foundation, Shionogi Pharma will seek to create a diverse modality CDMO based on the group’s unique knowledge, technology, and experience, including in the manufacturing of high pharmacological activity APIs and drug products, solid and injectable, while also aiming to establish a new continuous manufacturing platform for API.

* Contract Development and Manufacturing Organization


2. Absorption-type merger

(1) Summary of the Merger

           A)  Schedule of the Merger

                 Approval of Merger by Shionogi’s Board of Directors November 29, 2021

                 Approval of Merger agreement by Shionogi Pharma’s Board of Directors December 17, 2021 (planned)

                 Conclusion date of Merger agreement December 22, 2021 (planned)

                 Approval of Merger agreement by Shionogi Pharma Extraordinary General  Meeting of Shareholders February 2022 (planned)

                 Effective date of Merger April 1, 2022 (planned)

                 Registration date of Merger April 1, 2022 (planned)


           B)  Method of the Merger
                The Merger is an absorption-type merger under which Shionogi Pharma shall be the company surviving the Merger, and Nagase 

                Medicals shall be absorbed in the Merger.



(2) Outline of merging companies


Company surviving the Merger

(as of November 30, 2021)

Company absorbed in the Merger

(as of November 30, 2021)

Company Name

Shionogi Pharma Co., Ltd.

Nagase Medicals Co., Ltd.

Major Business


Manufacturing, sale, analytical testing

and pharmaceutical engineering of

medicinal drugs and investigational


Development, manufacture and

import/export of ethical drugs,

medical equipment, medical materials

and veterinary drugs

Date Established

October 1, 2018

July 1, 1972


5-1, Mishima 2-chome, Settsu, Osaka

323, Senzo 4-chome, Itami, Hyogo


President and CEO

Ryuichi Kume, Ph.D.

Representative Director and President Mitsuru Akasaka


90 million yen

498 million yen

End of Fiscal Year

March 31

March 31

Principal shareholders and

investment ratio

Shionogi & Co., Ltd.


Shionogi Pharma Co., Ltd.


3. Prospects
We expect the impact of the Merger on Shionogi’s consolidated business performance for the period ending March 31, 2022 to be minimal.


Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.


For Further Information, Contact:

SHIONOGI Website Inquiry Form : https://www.shionogi.com/global/en/contact.html



1.Press release on August 31, 2020
Shionogi Pharma to acquire Nagase Medicals as a wholly owned subsidiary